Forge Nano and Nanexa Enter Joint Development Agreement to Advance Manufacturing for ALD-Coated PharmaShell® Long-Acting Injectable Medicines

* Collaboration intended to develop large-scale, GMP-compliant ALD manufacturing equipment supporting Nanexa’s broad portfolio of proprietary and partnered PharmaShell® programs. DENVER and UPPSALA, Sweden, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Forge Nano, Inc., a leading U.S.-based semiconductor equipment and advanced materials company pioneering Atomic Layer Deposition (“ALD”) technology for artificial intelligence (“AI”)-era chip manufacturing and defense battery applications, which has signed an agreement to merge with Archimedes Tech SPAC Partners II Co. (“Archimedes II”) (NASDAQ: ATII), today announced a Joint Development Agreement (“JDA”) with Nanexa AB to develop scalable pharmaceutical manufacturing capabilities for Nanexa’s PharmaShell® drug delivery platform and its portfolio of proprietary and partnered programs.

Under the agreement, Forge Nano and Nanexa will collaborate on the development of a large scale GMP-compliant ALD manufacturing equipment intended to support clinical development and potential future commercial-scale production across the Nanexa’s PharmaShell® portfolio. The infrastructure and process know-how potentially gained through the collaboration will find its use in multiple PharmaShell®-enabled therapeutic programs.